Advances in the treatment of opioid dependence: Continued progress and ongoing challenges

JAMA

Volumn 304, Issue 14, 2010, Pages 1612-1614

  O'Connor, Patrick G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLMETHADOL; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; HYDROCODONE; ILLICIT DRUG; DRUG IMPLANT; METHADONE; NARCOTIC ANTAGONIST;

DETOXIFICATION; DRUG EFFICACY; HUMAN; NOTE; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; TREATMENT OUTCOME; DRUG IMPLANT; HEALTH CARE DELIVERY; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

BUPRENORPHINE; DRUG IMPLANTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; METHADONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 77957927438     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1496     Document Type: Note

References (15)

1. Substance Abuse and Mental Health Services Administration. Results From the 2009 National Survey on Drug Use and Health: Volume I - Summary of National Findings. Rockville, MD: Office of Applied Studies; 2010.
2. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future - National Results on Adolescent Drug Use: Overview of Key Findings, 2009. Bethesda, MD: National Institute on Drug Abuse; 2010.
3. Masson CL, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction. 2004;99(6):718-726.
4. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:646-650.
5. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303-2305.
6. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777-786.
7. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290-1297.
8. Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39(2):96-104.
9. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365-374. (Pubitemid 44127539)
10. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003-2011.
11. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576-1583.
12. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2)(suppl):S39-S47.
13. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA. 2005;294(8):903-913.
14. Das NG, Das SK. Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery. Drug Deliv. 2004;11(2):89-95.
15. Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE. An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction. 2006;101(3):420-432.